HPMA Nanomedicine: Targeting Cancer with Precision

Abstract

Polymer nanotherapeutics has gained prominent attention and is key in drug delivery systems. They explored widely explored tools to improve the solubility, stability, bioavailability, and prolonged circulation of therapeutic agents. Abraxane, Myocet, Daunoxone, and Doxil etc. are some successful examples of polymers approved for cancer treatment. Medicinal chemists have a vast landscape to select nanomaterials that include polymeric nanoparticles (PNPs), polymeric micelles (PMC), prodrugs, liposomes, and dendrimers etc. Polyethylene glycols (PEG), pHPMA (poly-N-2 hydroxypropyl methacrylamide), polyethylene, polystyrene etc. are widely used for drug delivery. This review highlights the importance of pHPMA in nano drug delivery. First, we review the chemical properties, pharmacology, and pharmacokinetics of pHPMA, then its synthetic routes of preparation. Second, we discuss pHPMA-based nano carriers and their therapeutic efficacy in cancer. In addition, we aim to discuss clinical status and future possibilities of pHPMA in combination immunotherapy. We aim to provide comprehensive information about current pHPMA-Nanotherapeutics to facilitate future development.